Scientific rationale and prerequisites for the use of direct oral anticoagulants for the prevention of thromboembolic complications in patients with COVID-19


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review presents an analysis of data on the use of direct oral anticoagulants for the prevention of thrombotic complications in patients with COVID-19, according to the results of published clinical studies, national guidelines for the management of patients with new coro-navirus infection, protocols of university hospitals, and clinical trials.

Full Text

Restricted Access

About the authors

V. A Otdelenov

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

A. V Matveev

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

K. B Mirzaev

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

D. A Sychev

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

References

  1. Deng Y., Liu W., Liu K., et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin MedJ (Engl). 2020;133(11):1261-57. doi: 10.1097/CM9.0000000000000824.
  2. Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg. Microb Infect. 2020;9(1):687-90. doi: 10.1080/22221751.2020.1741327.
  3. Thachil J., Tang N., Gando S., et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J ThrombHaemost. 2020;18(5):1023-26. doi: 10.1111/jth.14810.
  4. American Society of Hematology. COVID-19 and coagulopathy: frequently asked questions. From the ASH website. (Version 4.0; last updated September 24, 2020) [Internet]. [cited 2020 Nov 14]. Available from: https://www.hematology. org/covid-19/covid-19-and-coagulopathy.
  5. Tang N, Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb Haemost. 2020;18(4):844-47. doi: 10.1111/jth.14768.
  6. Guan W., Ni Z., Hu Y., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. Doi: 10.1056/ NEJMoa2002032.
  7. Wu C, Chen X., Cai Y., et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA. Intern. Med. 2020;180(7):934. Doi: 10.1001/ jamainternmed.2020.0994.
  8. Kunutsor S.K., Laukkanen J.A. Incidence of venous and arterial thromboembolic complications in COVID-19: A systematic review and metaanalysis. Thromb Res. 2020;196:27-30. doi: 10.1016/j.thromres.2020.08.022.
  9. Yale School Of Medicine. COVID-19 Treatment Algorithm. Updated 10/27/20 COVID-19 TREATMENT ADULT_10.27.2020_ 398806_5_v1.pdf.
  10. Временные методические рекомендации Министерства здравоохранения РФ по профилактике, диагностике и лечению новой коронавирусной инфекции (COVID-19), версия 9 от 26.10.2020 [Internet]. Cited 2020 Nov 15.
  11. Mount Sinai COVID-19 Anticoagulation Algorithm. Version 1.1 (April 9, 2020) [Internet]. [cited 2020 Nov 15]. Available from: https:// emergencymedicinecases.com/wp-content/ uploads/2020/04/COVID-19-Anticoagulation- Algorithm-version_final_1.1.pdf?
  12. Рекомендации МГНОТ по диагностике и интенсивной терапии синдрома диссеминированного внутрисосудистого свертывания крови при вирусном поражении легких. Под ред. П.А. Воробьева, В.А. Елыкомова. Проблемы стандартизации в здравоохранении 2020. C. 5-6. doi: 10.26347/1607-2502202005-06099-111.
  13. NIH COVID-19 Treatment Guidelines [Internet]. [cited 2020 Nov 15]. Available from: https:// www.covid19treatmentguidelines.nih.gov.
  14. UW Medicine COVID-19 Resource Site [Internet]. University of Washington. 2020. Available from: https://covid-19.uwmedicine.org/Pages/ default.aspx.
  15. Bikdeli B., Madhavan M.V., Jimenez D., et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. J Am Coll Cardiol. 2020;75(23):2950-73. Doi: 10.1016/ jjacc.2020.04.031.
  16. Brigham and Women's Hospital COVID-19 Protocols [Internet]. 2020. Available from: https:// covidprotocols.org.
  17. Massachusetts General Hospital (MGH) COVID-19 Treatment Guidance [Internet]. 2020 [cited 2020 Jun 26]. Available from: https://www. massgeneral.org/assets/MGH/pdf/news/coronavirus/mass-general-COVID-19-treatment-guidance.pdf.
  18. McBane R.D., Torres Roldan V.D., Niven A.S., et al. Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic. Mayo Clin Proc. 2020;95(11):2467-86. doi: 10.1016/j.mayocp.2020.08.030.
  19. Marietta M., Ageno W., Artoni A., et al. COVID-19 and haemostasis: A position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus. 2020;18(3):167-69. doi: 10.2450/2020.0083-20.
  20. Рекомендации по диагностике и интенсивной терапии синдрома диссеминированного внутрисосудистого свертывания крови при вирусном поражении легких. doi: 10.26347/1607-2502202005-06099- 111.
  21. Search of: DOAC OR rivaroxaban OR apixa-ban OR dabigatran COVID-19 - List Results -ClinicalTrials.gov [Internet]. [cited 2020 Nov 15]. Available from: https://clinicaltrials.gov/ct2/ results?cond=COVID-19&term=DOAC+OR+riva roxaban+OR+apixaban+OR+dabigatran&cntry= &state=&city=&dist.
  22. Iturbe-Hernandez T., Garcia de Guadiana Romualdo L., Gil Ortega I., et al. Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL* protocol. Drugs Context. 2020;9:1-12. Doi: 10.7573/ dic.2020-8-3.
  23. Angus D.C., Berry S., Lewis R.J., et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design. Ann Am Thorac Soc. 2020;17(7):879-91. Doi: 10.1513/ AnnalsATS.202003-192SD.
  24. Sivaloganathan H., Ladikou E.E., Chevassut T. COVID-19 mortality in patients on anticoagulants and antiplatelet agents. Br J Haematol. 2020;190(4).doi: 10.1111/bjh.16968.
  25. Cohen A.T., Spiro T.E., Buller H.R., et al. Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. N Engl J Med. 2013;368(6):513-23. doi: 10.1056/NEJMoa1111096.
  26. Goldhaber S.Z., Leizorovicz A., Kakkar A.K., et al. Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients. N Engl J Med. 2011;365(23):2167-77. doi: 10.1056/NEJMoa1110899.
  27. Flam B., Wintzell V., Ludvigsson J.F., et al. Direct oral anticoagulant use and risk of severe COVID-19. J Intern Med. 2020;joim.13205. doi: 10.1111/joim.13205.
  28. Testa S., Prandoni P., Paoletti O., et al. Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience. J Thromb Haemost. 2020;18(6):1320-23. doi: 10.1111/jth.14871.
  29. Detailed recommendations for interactions with experimental COVID-19 antiviral therapies. Updated 24 September 2020. University of Liverpool [Internet]. Available from: https:// www.covid19-druginteractions.org/prescribing-resources.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies